Avilex Pharma develops novel inhibitors of PDZ domain proteins to target a range of unmet medical needs. Our lead candidate AVLX-144 is a drug candidate for the treatment of ischemic stroke.
Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Ass. Prof. Anders Bach of the Department of Drug Design and Pharmacology.
Avilex Pharma and key partners receive an investment of DKK 20 mill. (total budget DKK 26 mill. / $4.0 mill.) from Innovation Fund Denmark to bring AVLX-144 to the clinic and develop a new PET marker.
© Copyright 2019 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK